0001209191-19-059089.txt : 20191204 0001209191-19-059089.hdr.sgml : 20191204 20191204164650 ACCESSION NUMBER: 0001209191-19-059089 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191202 FILED AS OF DATE: 20191204 DATE AS OF CHANGE: 20191204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LONGENECKER JOHN P PHD CENTRAL INDEX KEY: 0001288231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 191268627 MAIL ADDRESS: STREET 1: 10445 PACIFIC CENTER CT CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-02 0 0001396814 Pacira BioSciences, Inc. PCRX 0001288231 LONGENECKER JOHN P PHD C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 1 0 0 0 Common Stock 2019-12-02 4 M 0 872 1.61 A 10933 D Common Stock 2019-12-02 4 M 0 3128 1.61 A 14061 D Common Stock 2019-12-02 4 S 0 1300 46.132 D 12761 D Stock Option (Right to Buy) 1.61 2019-12-02 4 M 0 872 0.00 D 2020-09-02 Common Stock 872 0 D Stock Option (Right to Buy) 1.61 2019-12-02 4 M 0 3128 0.00 D 2020-09-02 Common Stock 3128 3736 D The option vested as to 25% of the options on September 2, 2011 and vested as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering. The option vested as to 75% of the options on September 2, 2010 and vested as to the remaining 25% of the options in successive equal monthly installments for the subsequent 12 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering. /s/ Kristen Williams, Attorney-in-Fact 2019-12-04